Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

Core Insights - Artisan Partners' "Artisan Small Cap Fund" reported strong performance in Q3 2025, with major US indices reaching record highs and the fund's Investor Class returning 8.69% [1] - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) showed significant stock performance, with a one-month return of 28.70% and a 76.15% increase over the past 52 weeks, closing at $553.42 per share with a market cap of $12.569 billion [2] - The fund increased its position in Madrigal Pharmaceuticals due to the successful launch of its FDA-approved drug Rezdiffra™ for treating MASH, indicating confidence in the company's market potential [3] Fund Performance - The Artisan Small Cap Fund's Investor Class fund ARTSX returned 8.69%, Advisor Class fund APDSX returned 8.75%, and Institutional Class fund APHSX returned 8.73% in Q3 2025, compared to a 12.19% return for the Russell 2000 Growth Index [1] Company Focus - Madrigal Pharmaceuticals is focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its lead drug, Rezdiffra™, which is the first FDA-approved treatment for MASH with moderate to advanced fibrosis [3] - The company reported net sales of $287 million in Q3 2025, reflecting a 35% increase quarter-over-quarter [4]